Robert Kruse, MD, PhD

@RobertLKruse

Physician Scientist, Aspiring Biotech Entrepreneur, Proud alumnus, Texan, Resident, Blog: Opinions are my own.

Vrijeme pridruživanja: travanj 2015.

Tweetovi

Blokirali ste korisnika/cu @RobertLKruse

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @RobertLKruse

  1. Prikvačeni tweet
    31. sij

    My article on outbreak is now online: "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China". Raced to write and revise in one week! Embracing to solve crisis.

    Poništi
  2. Proud to share that I'm working w/ two Chinese biotech companies to produce ACE2-Fc & advance it toward testing in infected patients. The must be stopped. If any US-based investors, foundations, or companies want to join the effort, please reach out.

    Poništi
  3. proslijedio/la je Tweet

    A race against time – we need therapies that can be rapidly tested to treat patients, while efforts continue. explains the potential of using ACE2-Fc biologic agent (opinion article awaiting )

    Poništi
  4. 4. velj

    Thinking about announcement to investigate neutralizing antibodies (NAbs) against , still a significant lead time to get a candidate. Moreover, almost all papers only use NAbs to prevent infection in SARS models, our best surrogate to the current virus

    Poništi
  5. proslijedio/la je Tweet

    Aiding global health efforts against - recommends pursuing ACE2-Fc biologic agent. He explains the potential benefits of using this agent, providing that manufacturing soon starts on an available sequence

    Poništi
  6. proslijedio/la je Tweet
    2. velj

    Wuhan Coronavirus Looks Increasingly Like a Pandemic, Experts Say - via ⁦

    Poništi
  7. 1. velj

    I wonder if could sell these plasmids for just a little less? If they want people to work on vaccines, therapies, and diagnostics around the world for this crisis, maybe saving researchers money or giving away for free rather than $420

    Poništi
  8. 1. velj

    A soluble, receptor decoy fused to an Fc domain (ACE2-Fc) should create a neutralizing antibody against that could treat & protect patients from infection. Virus couldn't mutate to escape therapy. Read more here:

    Poništi
  9. 1. velj

    For now, seemingly a surrogate virus with Vesicular Stomatitis Virus (VSV) pseudotyped with Spike protein could be utilized by many labs, similar to what they did in this study just published.

    Prikaži ovu nit
    Poništi
  10. 1. velj

    Has there been any discussion on how labs should be testing new therapies against ? If in vitro data is required, few labs are BSL-3 certified. If surrogate pseudotyped viruses are used, can we rely on that data? Mice shouldn't be naturally infectious, either.

    Prikaži ovu nit
    Poništi
  11. 31. sij

    Special thanks to the team for working with me to expedite publishing this past week to reach the research community quickly, important in this outbreak scenario.

    Poništi
  12. 22. sij

    Always amazing how the little details in CAR molecule design have such a big difference, here hinge and TM domain choice, and likely Ab has different affinity. Saw the same in my HBV CAR-T work on hinge length.

    Poništi
  13. 21. sij

    Proud to share my first publication while at and first in my field of transfusion medicine. We evaluated a platform by to perform automated ABO antibody titers in the blood bank. Applications in transplant medicine & more!

    Poništi
  14. 6. sij

    Not shocking that a linear ssDNA fragment might find its way to integrate into the genome, especially at high doses...

    Poništi
  15. Reminds me of my recent reviewer, who offered these gems: "unfortunately the paper is not well written", "lack in fundamental understanding", & "authors should familiarize themselves with the literature." Manuscript was accepted with minor edits.

    Poništi
  16. Mechanism explained:

    Prikaži ovu nit
    Poništi
  17. Cool paper. Could really improve ability to purify cell populations of interest in manufacturing of cell therapies. Example: Could capture CD3 T cells with aptamer, then add oligo antidote to seamlessly release. Very useful for the cell therapy field.

    Prikaži ovu nit
    Poništi
  18. proslijedio/la je Tweet

    Interested in ? Here's a new collection of freely accessible reviews - covering regulatory T cells for immune disorders, gamma delta T cells for cancer and engineered haematopoietic stem cells for blood disorders

    Poništi
  19. The eternal debate in transfusion medicine continues...

    Poništi
  20. To me, this is a major issue. Hard to see the FDA liking this, unless the risk-benefit ratio is there for these patients. But other methods can knockdown PD1 in T cells w/o risk.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·